Neurocrine Biosciences to Participate at Investor Conferences in December
NBIX Stock | USD 136.99 1.57 1.16% |
Slightly above 63% of all Neurocrine Biosciences' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that some traders are interested. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
Neurocrine |
Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at
Read at finance.yahoo.com
Neurocrine Biosciences Current Investor Sentiment
Panic Vs Confidence
63
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Neurocrine Biosciences' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Neurocrine Biosciences.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Neurocrine Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Neurocrine Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neurocrine Biosciences Fundamental Analysis
We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Neurocrine Biosciences is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Neurocrine Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.
Peers
Neurocrine Biosciences Related Equities
IRWD | Ironwood Pharmaceuticals | 3.15 | ||||
ANIP | ANI Pharmaceuticals | 1.61 | ||||
EVO | Evotec SE | 1.59 | ||||
PCRX | Pacira BioSciences, | 1.16 | ||||
ITCI | Intracellular | 0.66 | ||||
SUPN | Supernus Pharmaceuticals | 0.45 | ||||
PBH | Prestige Brand | 0.20 | ||||
DVAX | Dynavax Technologies | 0.31 | ||||
AMPH | Amphastar | 0.63 | ||||
ALKS | Alkermes Plc | 0.71 | ||||
AVDL | Avadel Pharmaceuticals | 1.65 | ||||
COLL | Collegium Pharmaceutical | 1.85 |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.